Close
Achema

Drug Research

Gritstone and CEPI Announce Agreement to Advance Second-Generation COVID-19...

Gritstone bio, Inc., a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, announced that the company entered into a funding agreement of...

Exelixis and Invenra expand partnership to develop cancer antibodies

Exelixis and Invenra have extended their discovery and licensing partnership to include 20 more oncology targets for multi-specific antibodies, antibody-drug conjugates, and the development of...

Sinopharm signs with Bangladesh to jointly produce COVID-19 vaccines

Chinese pharmaceutical giant Sinopharm has signed an agreement with Bangladesh over the co-production of COVID-19 inactivated vaccines.  Five million vaccines will be finished and dispensed...

Seagen and RemeGen enter up to $2.6bn deal for...

Seagen and a Chinese company, RemeGen, have signed an exclusive global licencing agreement to develop and market a new HER2-targeted antibody-drug conjugate (ADC), disitamab vedotin. Merging...

Heraeus completes multi-million Euro cancer therapy API capacity expansion

Heraeus Pharmaceutical Ingredients’ additional production line for Platinum-based highly potent active pharmaceutical ingredients (Pt hAPIs) is now fully operational at the company’s headquarters in Hanau,...

Next Generation Automation Lab Achieves Huge Productivity Gains

Eli Lilly and Company and their industry partners, including sample management specialists – Ziath, are speeding the discovery of new medicines through the fully automated...

Takeda and Frazier Healthcare Announce Collaboration to Launch HilleVax...

Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialize Takeda’s norovirus...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read